LESLIE DICKMANN

LESLIE DICKMANN

University of Wisconsin-Madison

H-index: 25

North America-United States

About LESLIE DICKMANN

LESLIE DICKMANN, With an exceptional h-index of 25 and a recent h-index of 17 (since 2020), a distinguished researcher at University of Wisconsin-Madison, specializes in the field of Drug Development, Pharmacy Education, ADME Sciences, Clinical Pharmacology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Quantitative systems pharmacology model‐based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3‐kinase inhibitors

Intrinsic and extrinsic pharmacokinetic variability of small molecule targeted cancer therapy

Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without …

Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors

LESLIE DICKMANN Information

University

Position

___

Citations(all)

2524

Citations(since 2020)

893

Cited By

1990

hIndex(all)

25

hIndex(since 2020)

17

i10Index(all)

37

i10Index(since 2020)

26

Email

University Profile Page

University of Wisconsin-Madison

Google Scholar

View Google Scholar Profile

LESLIE DICKMANN Skills & Research Interests

Drug Development

Pharmacy Education

ADME Sciences

Clinical Pharmacology

Top articles of LESLIE DICKMANN

Title

Journal

Author(s)

Publication Date

Quantitative systems pharmacology model‐based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3‐kinase inhibitors

CPT: Pharmacometrics & Systems Pharmacology

Kapil Gadkar

Christina Friedrich

Vincent Hurez

Maria‐Luisa Ruiz

Leslie Dickmann

...

2022/5

Intrinsic and extrinsic pharmacokinetic variability of small molecule targeted cancer therapy

Clinical and Translational Science

Eric Reyner

Bert Lum

Jing Jing

Matts Kagedal

Joseph A Ware

...

2020/3

Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without …

Cancer Research

Komal Jhaveri

Kevin Kalinsky

Philippe Bedard

Andres Cervantes

Cristina Saura

...

2020/2/15

Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors

Cancer Research

Dejan Juric

Kevin Kalinsky

Mafalda Oliveira

Andres Cervantes

Philippe Bedard

...

2020/2/15

See List of Professors in LESLIE DICKMANN University(University of Wisconsin-Madison)